MRNA vs TECH — Key Metrics
| Metric | MRNA (MODERNA INC) | TECH (BIO-TECHNE CORP) |
|---|---|---|
| Price | 196.79 | 72.75 |
| Market Cap | 79.63 Billion | 11.43 Billion |
| P/E (TTM) | -27.8 | 66.14 |
| P/B (Quarterly) | 15.043 | 5.284 |
| P/S (TTM) | 31.53 | 9.3 |
| Net Profit Margin (TTM) | -110.5 | 14.0 |
| Gross Margin (TTM) | 28.0 | 65.8 |
| ROE (TTM) | -37.6 | 8.2 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Greatly Underperform
Underperform
Recommendation Summary
Stock MRNA is projected to greatly underperform the market, stock TECH is projected to underperform the market. Upfront Recommendation: TECH.
Financial Metrics
| MRNA | Metrics | TECH |
|---|---|---|
| $196.79 | Price | $72.75 |
| — | Market Capitalization | — |
| 31.53 | Price to Sales | 9.3 |
| 112.62 | Price to Gross Profit | 14.15 |
| 29.96 | Price to R&D | 117.98 |
| 10.84 | Price to Current Assets | 13.86 |
MRNA vs TECH at a glance
Moderna INC (MRNA) and Bio-techne Corp (TECH) are both Biotechnology companies in the Healthcare sector. MRNA is the larger, at $79.6 billion in market value against $11.4 billion for TECH, about 7.0 times the size.
On trailing-twelve-month figures, MRNA trades at 31.5 times trailing sales and TECH at 9.3; net profit margins are -110.5% and 14.0%.
The Upfront Investment model currently rates MRNA Greatly Underperform and TECH Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.